Patent application number | Description | Published |
20090263353 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles - Compounds of a certain formula I, | 10-22-2009 |
20100120737 | Amorphous ciclesonide - The present invention relates to amorphous ciclesonide, methods to prepare the same, pharmaceutical compositions comprising amorphous ciclesonide as active ingredient, and methods of treatment using amorphous ciclesonide. | 05-13-2010 |
20100317565 | Novel Peptides and Their Use for the Treatment of Edema - The invention relates to novel peptides, which can be used for the production of pharmaceutical compositions. These pharmaceutical compositions can be used for the treatment of edema, in particular pulmonary edema. | 12-16-2010 |
20110086897 | (E)-N-(2-Amino-phenyl)-3--acrylamide salts - A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-beπzenesulfonyl]-1H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate. | 04-14-2011 |
20130012544 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase. | 01-10-2013 |
20140378509 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis. | 12-25-2014 |
20150080400 | Novel EP2 Receptor Agonists - The compounds of formula (1) | 03-19-2015 |
20150266965 | Method for Preparation of a High Concentration Liquid Formulation of an Antibody - The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof. | 09-24-2015 |